Supplement figure 1: Forest plot of included randomized controlled trials
Overall (I
2= 44.6%, p = 0.015)
BENAZEPRIL
ROAD-losartan VA NEPHRON D MDRD B
ONTARGET ORIENT
CAPTOPRIL STUDY
MDRD A
REIN 2
TRANSCEND ESCAPE Clinical Trial
acronym
FIELD
SUN MACRO IDNT
RENAAL AIPRI ALTITUDE
REIN ADVANCE AASK
SHARP
0.83 (0.75, 0.92) 0.69 (0.49, 0.99)
0.45 (0.20, 1.01) 0.63 (0.39, 1.00) 0.83 (0.66, 1.05) 1.07 (0.71, 1.62) 0.96 (0.73, 1.25) Relative risk
(95% CI)
0.63 (0.37, 1.07)
0.62 (0.37, 1.02)
1.12 (0.74, 1.69)
0.67 (0.19, 2.37) 0.62 (0.38, 1.03) 0.81 (0.46, 1.43)
1.35 (0.57, 3.19) 0.78 (0.62, 0.99)
0.75 (0.62, 0.90) 0.94 (0.06, 15.01) 1.07 (0.83, 1.38)
0.55 (0.36, 0.84) 1.19 (0.67, 2.12) 0.80 (0.60, 1.06)
0.98 (0.91, 1.05)
100.00 5.25
1.39 3.46 8.25 4.16 7.07 2.88
3.09
4.23
0.60 3.16 Weight
%
2.51
1.24 8.14
9.71 0.13 7.61
3.94 2.48 6.77
13.92
0.83 (0.75, 0.92) 0.69 (0.49, 0.99)
0.45 (0.20, 1.01) 0.63 (0.39, 1.00) 0.83 (0.66, 1.05) 1.07 (0.71, 1.62) 0.96 (0.73, 1.25) 0.63 (0.37, 1.07)
0.62 (0.37, 1.02)
1.12 (0.74, 1.69)
0.67 (0.19, 2.37) 0.62 (0.38, 1.03) 0.81 (0.46, 1.43)
1.35 (0.57, 3.19) 0.78 (0.62, 0.99)
0.75 (0.62, 0.90) 0.94 (0.06, 15.01) 1.07 (0.83, 1.38)
0.55 (0.36, 0.84) 1.19 (0.67, 2.12) 0.80 (0.60, 1.06)
0.98 (0.91, 1.05)
100.00 5.25
1.39 3.46 8.25 4.16 7.07 2.88
3.09
4.23
0.60 3.16 2.51
1.24 8.14
9.71 0.13 7.61
3.94 2.48 6.77
13.92
1.0
0.3 0.5 2.0
Relative Risk (95%CI)
Supplement table 1: JADAD score of the trials included in the meta-analysis.
Trial (year)
Was the study randomized
Appropriateness and description of the randomization
sequence
Was the study double blinded
Appropriateness and description of
the blinding procedure
Description of drop outs and withdrawal
Jadad Score
AASK (2001) 1 0 1 1 1 4
ADVANCE (2001) 1 1 1 1 1 5
AIPRI (1999) 1 0 1 1 1 4
ALTITUDE (2012) 1 1 1 1 1 5
BENAZIPRIL (2009) 1 1 1 1 1 5
CAPTOPRIL (2006) 1 1 1 1 1 5
ESCAPE (2009) 1 1 1 1 1 5
FIELD (2005) 1 1 1 1 1 5
IDNT (2001) 1 1 1 1 1 5
MDRD A (1994) 1 0 1 1 1 4
MDRD B (1994) 1 0 1 1 1 4
ONTARGET (2008) 1 1 1 1 1 5
ORIENT (2011) 1 1 1 1 1 5
VA NEPHRON D (2013) 1 0 1 1 1 4
REIN (2000) 1 1 1 1 1 5
REIN 2 (2005) 1 1 1 1 1 5
RENAAL (2001) 1 1 1 1 1 5
ROAD (2007) 1 1 1 1 1 5
SHARP (2011) 1 1 1 1 1 5
SUN MACRO (2012) 1 0 1 1 1 4
TRANSCEND (2008) 1 1 1 1 1 5
Supplement Figure 2: Funnel plot for assessing publication bias(with pseudo 95%
confidence intervals)
0.511.5
-3 -2 -1 0 1 2 3
Log Relative Risk for ESRD
Standard Error of Log Relative Risk
Appendix 1: Search strategy Database Search terms
PubMed
proteinuria [mh] OR kidney diseases[mh] AND (drug therapy[sh] OR drug effects[sh]) AND (endstage renal disease OR end-stage renal disease OR dialysis OR ESRD OR renal replacement therapy) AND randomized controlled trial[pt]AND humans[mh] NOT (comment[pt] OR letter[pt] OR editorial[pt])
